RenovoRx (RNXT) Q3 FY2026 earnings: revenue $1 million, up 300.8% on the year
RenovoRx, Inc. (RNXT) reported revenue of $1 million for Q3 FY2026, the quarter ended 30 September 2026, up 300.8% on the same quarter a year earlier. Net income was -$4 million, and diluted earnings per share $-0.08. The figures are the company's own, from the 10-Q it filed with the SEC on 5 November 2026.
Revenue
$1 million
+300.8% on the year · +17.3% on the quarter
Q1 FY2025Q3 FY2026
Operating margin
-303.6%
-1203.0% a year earlier
Q1 FY2025Q3 FY2026
Net income
-$4 million
Q1 FY2025Q3 FY2026
Diluted EPS
-$0.08
Q1 FY2025Q3 FY2026
this quarterthe same quarter a year earlierHover a bar for its figure.
What management said
Guidance figures: 3 kept.
Revenue rose nearly 300% year over year: Third-quarter revenue was $1.07 million, against $266,000 a year earlier, and up 17% from the second quarter. Management attributed the growth to RenovoCath commercialization and cancer center adoption.
First commercial use in sarcoma: In August 2026, an existing commercial customer used the device to treat a sarcoma patient, the first commercial use in a solid tumor beyond pancreatic cancer.
Gross margin near 82%: Gross profit was $878,000, a gross margin of about 82%, compared with about 80% a year earlier.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Operating cash flow
-2.5
-2.9
-2.3
Capital expenditure
0.0
0.1
0.0
-73.2%
Free cash flow
-2.6
-2.9
-2.3
Free cash flow margin
-240.0%
-323.2%
-853.4%
Cash from investing
-0.0
-0.1
0.0
Cash from financing
3.5
0.1
0.0
+6,232.7%
Depreciation and amortisation
n/a
n/a
1.0
Share-based compensation
0.5
0.6
0.3
-17.7%
+34.4%
Diluted shares, weighted
48m
47m
37m
+1.9%
+31.5%
Shares outstanding at period end
48m
45m
37m
+6.8%
+31.5%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Shareholders' equity
9.3
9.0
8.1
+3.4%
+14.9%
Debt
0.0
0.0
0.0
Operating lease liabilities
0.2
0.3
0.1
-13.1%
+67.9%
Other liabilities
2.9
2.2
3.0
+31.1%
-2.2%
Total liabilities and equity
12.4
11.5
11.2
+8.4%
+11.0%
Fixed assets
0.1
0.1
0.0
-5.3%
+584.6%
Cash and equivalents
10.4
9.5
10.0
+9.8%
+3.6%
Receivables
0.6
0.5
0.2
+26.9%
+260.4%
Inventory
0.3
0.4
0.3
-11.0%
+25.4%
Other assets
1.0
1.0
0.7
-4.1%
+40.4%
Total assets
12.4
11.5
11.2
+8.4%
+11.0%
Questions
What was RenovoRx's revenue in Q3 FY2026?
RenovoRx (RNXT) reported revenue of $1 million for Q3 FY2026, the quarter ended 30 September 2026, up 300.8% on the same quarter a year earlier.
How much did RenovoRx earn in Q3 FY2026?
Net loss for Q3 FY2026 was $4 million, and the diluted loss per share $0.08.
When did RenovoRx report Q3 FY2026 results?
RenovoRx filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 5 November 2026.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 30 September 2026, filed 5 November 2026: the filing.